Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer’s Sutent shows effectiveness as adjuvant therapy for RCC

Pfizer’s Sutent shows effectiveness as adjuvant therapy for RCC

10th October 2016

Pfizer has announced new data from the phase III S-TRAC study, showing the effectiveness of the renal cell carcinoma (RCC) drug Sutent when used as an adjuvant therapy.

Results from the S-TRAC trial showed that following one year of treatment, the median time until disease recurrence in participants treated with Sutent after surgery was 6.8 years, compared with 5.6 years for patients treated with placebo.

Adjuvant therapies are used to reduce the likelihood of cancer returning after initial treatment such as surgery. This study showed that Sutent was associated with an overall risk reduction of 24 percent.

Based on the results of the S-TRAC trial, Pfizer will be conferring with global regulatory authorities to establish potential next steps for the development of the drug.

First approved in the US in 2006 for the treatment of advanced RCC, Sutent is currently approved in 119 countries.

Dr Mace Rothenberg, chief development officer for oncology at Pfizer Global Product Development, said: "For the past ten years, Pfizer has been a leader in developing new treatments for patients with kidney cancer, and Sutent has been the most widely-prescribed first-line treatment for thousands of patients with advanced RCC around the world."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801826511-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.